Document |
Document Title |
WO/2021/122249A1 |
Process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is reacted with a cyclic compound comprising a cyclic compound having at least one nitrogen as ring member, bearing a substitutable hydrogen residue (cyclic...
|
WO/2021/127301A1 |
4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarb...
|
WO/2021/115881A1 |
The invention relates to a single-component mass, which is liquid at ambient temperature and which can be fixed via irradiation with actinic radiation and can be cured via the influence of moisture. The mass comprises at least the follow...
|
WO/2021/116820A1 |
The present invention relates to an improved process for the preparation of Benoxaprofen of formula (I) and its intermediate compounds of (II) & (IV) thereof.
|
WO/2021/115380A1 |
Disclosed is a compound having a neuroprotective effect, a preparation method therefor and a use thereof. Specifically, the compound has the structure shown by formula A, the definition of each group and substituent being as described in...
|
WO/2021/117846A1 |
The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase. The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically accept...
|
WO/2021/102567A1 |
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors....
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
WO/2021/097107A1 |
Described herein is new crystalline forms of the MAGL inhibitor 2-(2-((4-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)p
iperazin-1-yl)methyl)-5-(trifluoromethyl)phenoxy)-2-methylpr
opanoic acid, or a pharmaceutically acceptable salt...
|
WO/2021/093809A1 |
Disclosed are a new crystal form of tafamidis (compound I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of a drug for treating diseases caused...
|
WO/2021/097110A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
WO/2021/076691A1 |
Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as define...
|
WO/2021/076688A1 |
Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as define...
|
WO/2021/073643A1 |
The present application relates to the field of medicine, relates to drugs for treating non-alcoholic steatohepatitis, in particular, to linked cyclic compounds for treating non-alcoholic steatohepatitis, more in particular, to a compoun...
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
WO/2021/066608A1 |
The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a production method therefor. The compound represented by chemical formula 1, according to the present invention, has an excellent ...
|
WO/2021/060277A1 |
Provided are, inter alia, compounds useful as aminating agents capable of introducing an amino group protected by a deprotectable protecting group into a wide range of substates under relatively moderate conditions, an aminating agent ha...
|
WO/2021/058970A1 |
A method of identifying a first object, the method comprises: providing a first object comprising a material, the material comprising a polymer and a luminescent compound; and detecting an absorption and/or excitation and/or emission spe...
|
WO/2021/057852A1 |
The present invention relates to the field of agricultural protection. Disclosed are an oxazoline compound, a synthesis method therefor and an application thereof. The oxazoline compound has a structure represented by formula (I), wherei...
|
WO/2021/055627A1 |
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...
|
WO/2021/037022A1 |
Disclosed is a method for preparing 4-methyl-5-alkoxy oxazole, which belongs to the field of chemical synthesis. The method comprises subjecting a N-formylalaninate ester to a cyclization reaction to obtain the 4-methyl-5-alkoxy oxazole....
|
WO/2021/032857A1 |
The invention provides the imidazole, oxazole and thiazole compounds and use thereof in methods for treating a disease or a disorder, such as infectious diseases and cancer, wherein inhibition of sphingosine-1-phosphate lyase is benefici...
|
WO/2021/033504A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution is introduced into a flow path (I); the triphosgene solution comes into contact with a solid catalyst, which is affixed to at least a...
|
WO/2021/033505A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution, a tertiary amine solution and an active hydrogen-containing compound solution are introduced into different flow paths and are cause...
|
WO/2021/031533A1 |
Disclosed in the present invention is a method for synthesizing N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone, wherein the synthesis method involves: 3-R 2-4-R 1-phenylamine and epoxy chloropropane being used as raw materials to c...
|
WO/2021/032209A1 |
Provided are a compound of formula (I-a), an isomer thereof or a pharmaceutically acceptable salt thereof as a Hemagglutinin inhibitor, and a preparation method thereof. The compound is useful for preparing a medicament for treating a di...
|
WO/2021/028512A1 |
The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods ...
|
WO/2021/029146A1 |
Provided are: a polymerizable composition including a compound indicated by general formula (I–1) or general formula (I–2) and a polymerizable compound; an application therefor; a compound indicated by general formula (II); and an ap...
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
WO/2021/018834A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use fo...
|
WO/2021/018833A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
WO/2021/001858A1 |
The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of card...
|
WO/2020/263484A1 |
This document relates to methods and materials for treating a neuromyelitis optica (NMO) spectrum disorder such as NMO. For example, one or more tetracycline antibiotics can be administered to a mammal having, or at risk of developing, a...
|
WO/2020/264499A1 |
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligas...
|
WO/2020/257043A1 |
The embodiments of present invention provide processes and intermediates for the preparation of D1 PAM I: Formula (I).
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
WO/2020/249957A1 |
Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: Formula (I), wherein (AA) represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are ...
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
WO/2020/242277A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising: a naphthoquinone or benzoindazole compound which increases the ratio of NAD+ and NAD+/NADH through activi...
|
WO/2020/238559A1 |
Disclosed are a de-C2-symmetric diphenylamine-type chiral bisoxazoline ligand as shown in formula 3, a synthesis method therefor and the use thereof in an asymmetric catalytic reaction. The C2-symmetry of the ligand is removed by introdu...
|
WO/2020/232852A1 |
Disclosed in the present invention are an organic light-emitting material and a preparation method therefor, and an organic light-emitting device. The organic light-emitting material comprises a benzophenanthrene derivative which has goo...
|
WO/2020/232655A1 |
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...
|
WO/2020/232325A1 |
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
|
WO/2020/230134A1 |
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral...
|
WO/2020/225569A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...
|
WO/2020/222118A1 |
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
|
WO/2020/216298A1 |
Disclosed are a compound as shown in formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound of formula I and use of th...
|
WO/2020/207753A1 |
The present invention relates to an improved process for the preparation of 1-deoxy-1-methylamino-D- glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate, also known as tafamidis meglumine. The process of the present invention is par...
|